YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP's positive opinion in its decision on whether to grant a Marketing Authorisation by August 2011...
Free Skin Cancer Screenings
5/20/2011
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community...
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study...
A Handy, Quick And Flat Microscope To Detect Melanoma
5/20/2011
Suspicion of melanoma: In the future, doctors can pull out a new type of microscope to get to the bottom of suspicious changes in the skin. It provides a high-resolution image of skin areas of any size - and so quickly that you can hold it in your hand without blurring the resulting picture...
Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced today that it will meet with the U.S. Food and Drugs Administration's (the "FDA") Office of Oncology Drug Products in early June to discuss the re-submission of CTI's New Drug Application ("NDA") for pixantrone for accelerated approval to treat patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL")...
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc...
New Drug Target Discovered For Squamous Cell Carcinoma
5/20/2011
Researchers at Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma - the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., have found that a protein called alpha-catenin acts as a tumor suppressor and they also have unlocked the mechanism by which this protein controls cell proliferation...
Ovarian Cancer Drug Olaparib Extends Progression Free Survival
5/20/2011
A Phase II trial showed that Olaparib significantly extends progression-free survival of participants with SOC (platinum-sensitive relapsed serous ovarian cancer) who had completed chemotherapy. Makers AstraZeneca are presenting their findings at the ASCO (American Society of Clinical Oncology) 2011 annual meeting (abstract #5003)...
DNA Repair System Affects Colon Cancer Recurrence And Survival
5/19/2011
Colorectal cancer patients with defects in mismatch repair - one of the body's systems for repairing DNA damage--have lower recurrence rates and better survival rates than patients without such defects, according to a study published online May 19th in the Journal of the National Cancer Institute. About 15% of colorectal cancers are associated with mismatch repair defects...
Among patients referred by non-dermatologists to dermatologists for evaluation of skin lesions suspected of being malignant, only apparently one-fifth were found to be cancerous, although dermatologists identified and biopsied other incidental lesions, approximately half of which were malignant, according to a report in the May issue of Archives of Dermatology, one of the JAMA/Archives journals...